The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
about
Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLACombination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinomaA concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016Hepatocellular carcinoma: Where are we?Radiofrequency ablation of liver tumorsSystematic review of actual 10-year survival following resection for hepatocellular carcinomaModified high dorsal procedure for performing isolated anatomic total caudate lobectomy (with video)Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysisHepatocellular carcinoma among cirrhotics--utility of screening and surveillance programs--review articleHepatocellular carcinoma: A comprehensive reviewUnresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.Management strategies for hepatocellular carcinoma: old certainties and new realities.Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria?Advances in non-surgical management of primary liver cancer.Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma.Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE.Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systemsDirect ex vivo analysis of dendritic cells in patients with hepatocellular carcinomaRadiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolizationChemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review.Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma.Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis.Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolizationRole of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationImaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy.Research reporting standards for radioembolization of hepatic malignancies.Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitisThe p53R172H mutant does not enhance hepatocellular carcinoma development and progression.MRI features of hepatocellular carcinoma related to biologic behaviorHepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
P2860
Q24672943-D445C240-D5CC-47B0-A4C0-2577ED4779C6Q26471711-9BD3FA9D-3235-45B1-BA1F-9897EB9A5671Q26752478-7752123B-10F2-4FC3-888C-2B07FFEA371DQ26765182-8F206B61-7CB5-4233-A653-62E07FBF1D40Q26853330-3CE971C0-9B43-4E20-AEA8-ED4BC96053BBQ26998612-E8B1A725-D819-4249-A575-EE2369876918Q27303895-96CFFB15-8E2B-486E-9E07-148B87090E61Q28067391-A579770A-4758-443F-A0A1-144CE9D418E2Q28081456-5542B7F8-A2F4-4ED1-A583-DC31B6965C84Q28087638-3DD390D0-0202-4074-B7E7-23DBC3D7416FQ30248206-BBCA387E-00F8-4189-B22B-1219D15A9292Q30252143-C6B2455B-2B6E-4DB0-8397-AAC5E8F024B3Q30410247-190195CD-26C6-402A-AC99-619704D548F4Q30423781-FDA5336A-212D-4EC8-9DA4-C6B1867BFC96Q30468280-D75694D6-11A2-4214-B224-4599E1191823Q33514753-19BDD795-9DD1-4341-9217-B90569FCC33EQ33555339-BB49784B-0807-4EC3-A08C-24BD5899F067Q33576986-9778A30A-8E5D-4038-AF6E-9A15E2CDCF04Q33620645-BF32D1AA-CFF6-408C-9917-68FE5CA78851Q33718951-6DCCA5D7-F316-408A-B390-85234FB3DC54Q33721747-FD67F802-5C94-4653-A537-B7844CDF1B31Q33868428-283AEE27-02D8-4E26-A1C0-A9E64D2CF519Q34065098-819A6202-B470-4775-8C2A-1F2846D2A535Q34168811-7BAF8F6E-31BB-47E6-9370-4FBCA3471DA5Q34446810-29753563-9293-4FA5-AA56-B7AF014C2D3AQ34617414-42045853-550D-4B3B-93F5-7FD8623B1441Q34623730-D21D9D48-3AFF-49FE-95C7-B70504E1CE21Q34659484-F553F43C-F8F6-45B3-A28E-07A3009AAA8CQ34776673-BDA259A5-F7CB-40CE-A6B4-6D080A7CD27DQ34783408-1F9A792B-392B-4AB8-AB97-22A6BBFABFE6Q34982068-60FD9BB0-3E3F-4DDE-8889-B8F647778150Q35051942-A8A9A3A1-E729-444C-853B-43C377170E7DQ35073362-FADEF807-E38E-4DF8-B863-DFDA0C21601EQ35111887-741F7A0C-359C-469E-A7A0-CE8B7C7F2093Q35165793-BFCFC078-5C78-45A2-9B5F-65D39328E1D5Q35605993-41BB7956-420F-4DE4-8AF9-00F496E9FFA7Q35619951-25376F89-7C8A-461E-8F86-0ECFD1DC348DQ35626757-FCD1F31D-F3BF-4D6E-A5DF-C5B5DDF920EEQ35669106-B37EC81C-452F-4152-B704-482D82DFDCE1Q35716344-60FEC541-A1E4-4939-942B-F860F127CAAD
P2860
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@ast
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@en
type
label
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@ast
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@en
prefLabel
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@ast
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@en
P2093
P356
P1476
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.
@en
P2093
Barcelona-Clínic Liver Cancer Group
Jordi Bruix
Josep Fuster
P304
P356
10.1002/LT.20034
P433
P577
2004-02-01T00:00:00Z